Neurology and Therapy,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 30, 2024
Friedreich
Ataxia
(FA)
is
a
multisystem
neurodegenerative
disease.
Affected
individuals
rely
on
mobility
assistive
technologies
(MAT)
(e.g.
wheelchairs)
and
require
long-term
treatments
care.
To
analyse
the
patients'
health-related
quality
of
life
(HRQoL),
EuroQol
5
Dimension
3
Level
survey
(EQ-5D-3L)-a
widely
used
recommended
generic
measure-is
in
clinical
health
economic
studies.
Concerns
about
using
instrument
mobility-impaired
who
might
have
difficulties
finding
appropriate
response
options
for
mobility-related
items
led
us
to
investigate
how
3L
dimensions
perform
patients
with
FA
or
not
MAT.
Movement Disorders Clinical Practice,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 28, 2025
Abstract
Background
Clinical
outcomes
assessments
(COAs)
in
spinocerebellar
ataxia
(SCA)
need
to
be
standardized,
ataxia‐specific,
sensitive
change,
clinically
relevant,
and
meaningful
patients.
Objectives
To
evaluate
the
longitudinal
1‐
2‐year
performances
of
different
patient
reported
outcomes,
including
Patient
Reported
Outcome
Measure
Ataxia
(PROM‐Ataxia),
clinician
FARS
SARA,
those
with
early
manifest
symptoms
SCA
1,
2,
3,
6.
Methods
We
studied
53
patients
stage
SCA1‐3
SCA6
from
The
Instrumented
Data
Exchange
for
Study
24
age‐matched
healthy
controls.
Participants
were
seen
every
6
months
2
years.
Mixed
models
used
estimate
change
over
12‐
24‐months
follow‐up.
Changes
on
FARS‐FS
PGI‐C
as
anchors
changes.
Results
Among
persons
SCA,
mean
age
was
48.7
years
SARA
score
9.3.
Few
measures
showed
statistically
significant
changes
at
12
months.
At
24‐months,
FARS‐ADL,
PROM‐Ataxia
total,
physical,
ADL
scores
strongest
associations
change.
Conclusions
or
derived
outcome
measures,
such
FARS‐ADL
sub
domain
PROM‐Ataxia,
can
capture
patients’
symptom
experience
a
period
its
impact
daily
activities,
even
disease.
More
work
is
needed
identify
that
reliably
earlier.
The Cerebellum,
Journal Year:
2024,
Volume and Issue:
23(5), P. 2012 - 2027
Published: May 7, 2024
Abstract
The
functional
Scale
for
the
Assessment
and
Rating
of
Ataxia
(f-SARA)
assesses
Gait,
Stance,
Sitting,
Speech.
It
was
developed
as
a
potentially
clinically
meaningful
measure
spinocerebellar
ataxia
(SCA)
progression
clinical
trial
use.
Here,
we
evaluated
content
validity
f-SARA.
Qualitative
interviews
were
conducted
among
individuals
with
SCA1
(
n
=
1)
SCA3
6)
healthcare
professionals
(HCPs)
SCA
expertise
(USA,
5;
Europe,
3).
Interviews
symptoms
signs
relevance
f-SARA
concepts
SCA.
HCP
cognitive
debriefing
conducted.
recorded,
transcribed,
coded,
analyzed
by
ATLAS.TI
software.
Individuals
3
reported
85
symptoms,
signs,
impacts
All
indicated
difficulties
walking,
stance,
balance,
speech,
fatigue,
emotions,
work.
considered
Speech
relevant
concepts;
Sitting
(42.9%).
HCPs
Gait
relevant;
5
(62.5%)
Stance
relevant.
late-stage
disease
indicator.
Most
suggested
inclusion
appendicular
items
would
enhance
relevance.
Cognitive
supported
clarity
comprehension
Maintaining
current
abilities
on
1
year
most
3.
changes
stability
in
score
over
1–2
years,
1–2-point
change
total
score,
deviation
from
natural
history.
These
results
support
assessing
trials.
The Cerebellum,
Journal Year:
2024,
Volume and Issue:
23(4), P. 1478 - 1489
Published: Jan. 27, 2024
This
study
aimed
to
assess
the
responsiveness
rehabilitation
of
three
trunk
acceleration-derived
gait
indexes,
namely
harmonic
ratio
(HR),
short-term
longest
Lyapunov's
exponent
(sLLE),
and
step-to-step
coefficient
variation
(CV),
in
a
sample
subjects
with
primary
degenerative
cerebellar
ataxia
(swCA),
investigate
correlations
between
their
improvements
(∆),
clinical
characteristics,
spatio-temporal
kinematic
features.
The
acceleration
patterns
antero-posterior
(AP),
medio-lateral
(ML),
vertical
(V)
directions
during
21
swCA
were
recorded
using
magneto-inertial
measurement
unit
placed
at
lower
back
before
(T0)
after
(T1)
period
inpatient
rehabilitation.
For
comparison,
age-
speed-matched
healthy
(HS
CPT Pharmacometrics & Systems Pharmacology,
Journal Year:
2024,
Volume and Issue:
13(8), P. 1327 - 1340
Published: May 21, 2024
Abstract
The
Scale
for
the
Assessment
and
Rating
of
Ataxia
(SARA)
is
widely
used
assessing
severity
progression
genetic
cerebellar
ataxias.
SARA
now
considered
a
primary
end
point
in
several
ataxia
treatment
trials,
but
its
underlying
composite
item
measurement
model
has
not
yet
been
tested.
This
work
aimed
to
evaluate
properties
items
using
response
theory
(IRT)
demonstrate
applicability
across
even
ultra‐rare
Leveraging
subscores
data
from
1932
visits
990
patients
Autosomal
Recessive
Cerebellar
Ataxias
(ARCA)
registry,
we
assessed
performance
IRT
methodology.
characteristics
were
evaluated
over
range
entire
population
as
well
assessment
validity
115
ARCA
subpopulations.
A
unidimensional
was
able
describe
data,
indicating
that
captures
one
single
latent
variable.
All
had
high
discrimination
values
(1.5–2.9)
effectiveness
differentiating
between
subjects
with
different
disease
statuses.
Each
contributed
7%
28%
total
informativeness.
There
no
evidence
differences
subpopulations
applicability.
These
results
show
good
ability
all
adding
informational
value.
framework
provides
thorough
description
on
level,
facilitates
utilization
clinical
outcome
upcoming
longitudinal
natural
history
or
large
number
ataxias,
including
ones.
The Cerebellum,
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 12, 2024
This
study
aimed
to
generate
evidence
support
psychometric
validity
of
the
modified
functional
Scale
for
Assessment
and
Rating
Ataxia
(f-SARA)
among
patients
with
spinocerebellar
ataxia
(SCA).
Psychometric
measurement
properties
minimal
change
thresholds
f-SARA
were
evaluated
using
data
from
a
cohort
SCA
subjects
(recruited
at
Massachusetts
General
Hospital
[MGH];
n
=
33)
phase
3
trial
troriluzole
in
adults
(NCT03701399
[Study
206];
217),
including
subset
SCA3
genotype
(n
89).
item
ceiling
effects
absent
within
MGH
cohort,
while
floor
present.
Excellent
internal
consistency
reliability
was
demonstrated
(α
European Journal of Neurology,
Journal Year:
2025,
Volume and Issue:
32(1)
Published: Jan. 1, 2025
Abstract
Background
Friedreich
ataxia
is
a
rare
neurodegenerative
disorder
caused
by
frataxin
deficiency.
Both
underweight
and
overweight
occur
in
mitochondrial
disorders,
each
with
adverse
health
outcomes.
We
investigated
the
longitudinal
evolution
of
anthropometric
abnormalities
hypothesis
that
both
weight
loss
gain
are
associated
faster
disease
progression.
Methods
Participants
were
drawn
from
European
Friedreich's
Ataxia
Consortium
for
Translational
Studies
(EFACTS).
Age‐
sex‐specific
BMI
height
scores
calculated
using
KIGGS‐BMI
percentiles
children.
Height
correction
was
applied
scoliosis.
Longitudinal
data
analysed
linear
mixed
effects
models
incremental
standard
deviation
growth
mixture
identified
subclasses
varying
trajectories.
Results
Five
hundred
forty‐three
adults
fifty‐nine
children
assessed
up
to
5
years.
In
children,
severe
(26%),
(7%),
short
stature
(16%)
(23%)
common.
The
corrected
percentile
stable
although
48%
had
negative
over
1
year
63%
3
years
versus
10%/year
normal
reference
cohort.
Overweight
common
(19%),
slight
increase
time.
Longer
GAA
repeat
size
linked
lower
adults.
Weight
trajectory
not
progression
Conclusion
Significant
identified,
prevalent
These
findings
highlight
need
regular
nutritional
monitoring
interventions
manage
promote
healthy
Movement Disorders Clinical Practice,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 12, 2025
Abstract
Background
Hereditary
cerebellar
ataxia
(HCA)
represents
a
complex
group
of
disorders,
with
wide
spectrum
neurological
symptoms.
Among
these,
non‐ataxia
movement
disorders
(MD)
have
been
increasingly
acknowledged,
variable
frequency
across
different
forms.
Objectives
To
characterize
the
type
and
MD
in
patients
HCA.
identify
factors
associated
analyze
their
impact
on
disability.
Methods
We
conducted
prospective
study
starting
2017,
annual
visits
according
to
structured
protocol.
Patients
were
selected
from
database
clinical
genetic
features
analyzed.
Results
The
cohort
comprised
193
symptomatic
patients.
Machado‐Joseph
disease
(MJD,
also
SCA3
or
ATX‐
ATXN3
)
ataxia,
neuropathy
vestibular
areflexia
syndrome
(ATX‐
RFC1
most
common
autosomal
dominant
(AD)
recessive
forms,
14.0%
15.0%,
respectively.
present
95
(54.4%),
dystonia
being
(49.2%).
Tremor
was
identified
10.9%,
Parkinsonism
4.1%
chorea
3.6%
Myoclonus
tics
rare
(2.6%
0.5%).
presence
AD
inheritance
.
MD,
regardless
type,
correlated
higher
SARA
score
at
baseline,
increased
fall
frequency,
confinement
wheelchair,
earlier
occurrence
falls
permanent
use
walking
aid.
Conclusions
Movement
particularly
dystonia,
our
cohort.
This
highlights
possible
role
cerebellum
but
extra‐cerebellar
involvement
some
Presence
significantly
worsened
motor
disability,
highlighting
need
for
strategies
early
identification
tailored
management.